Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Microbiology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Microbiology. Displaying page 5 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2020-002312-43 Sponsor Protocol Number: 01052020 Start Date*: 2020-05-28
    Sponsor Name:Miguel Cervero Jiménez, servicio de Medicina Interna, Hospital Universitario Severo Ochoa
    Full Title: Clinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-1...
    Medical condition: COVID-19 PNEUMONIA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005573-12 Sponsor Protocol Number: LP0162-1335 Start Date*: 2022-10-05
    Sponsor Name:LEO Pharma A/S
    Full Title: A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004108-16 Sponsor Protocol Number: HOFATA_v3.0 Start Date*: 2022-04-21
    Sponsor Name:Medical University Vienna
    Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study
    Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003772-37 Sponsor Protocol Number: CTBM100C2302 Start Date*: 2006-01-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects
    Medical condition: Pulmonary pseudomonas aeruginosa infections in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    10011762
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) GR (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021983-14 Sponsor Protocol Number: MLK002 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to treat BOS.
    Medical condition: -Mortality at 1 and 2 year post diagnosis of BOS -Infection rate during BOS -Evolution of pulmonary function after diagnosis of BOS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003202-82 Sponsor Protocol Number: MK7655A-016 Start Date*: 2019-07-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Pip...
    Medical condition: Hospital-Acquired Bacterial Pneumonia / Ventilator-Associated Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-004469-11 Sponsor Protocol Number: PP-SA-001 Start Date*: 2022-01-11
    Sponsor Name:PHERECYDES PHARMA
    Full Title: PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus ...
    Medical condition: knee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004924-14 Sponsor Protocol Number: BSTEP Start Date*: 2022-04-21
    Sponsor Name:Leiden University Medical Center
    Full Title: New treatment strategy for patients with multiple recurrent Clostridioides difficile infection with bezlotoxumab as first option
    Medical condition: recurrent C. difficile infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10009657 Clostridium difficile colitis PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    20.0 10021881 - Infections and infestations 10012734 Diarrhea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004037-17 Sponsor Protocol Number: 19_RIPH1_07 Start Date*: 2021-07-28
    Sponsor Name:Centre Hospitalier Universitaire de Martinique
    Full Title: Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overse...
    Medical condition: Mild Leptospirosis : defined as Leptospirosis without the following severity criteria : a. Hemodynamic failure* with onset of septic shock b. Hematologic failure* with hemoglobin requiring red blo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024238 Leptospirosis PT
    20.0 10021881 - Infections and infestations 10024241 Leptospirosis, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003675-36 Sponsor Protocol Number: COLO/DPI/02/06 Start Date*: 2005-04-28
    Sponsor Name:Forest Laboratories UK Ltd
    Full Title: A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOB...
    Medical condition: Pseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001515-31 Sponsor Protocol Number: NEOMERO-1 Start Date*: 2011-08-25
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL
    Medical condition: late onset sepsis in the neonate and infant up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10053840 Bacterial sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004339-35 Sponsor Protocol Number: AR-301-002 Start Date*: 2019-01-16
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) c...
    Medical condition: Staphylococcus aureus pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035734 Pneumonia staphylococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FR (Completed) LV (Completed) BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001396-16 Sponsor Protocol Number: OP0595-6 Start Date*: 2023-03-29
    Sponsor Name:Meiji Seika Pharma Co., Ltd.
    Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur...
    Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10080628 Complicated urinary tract infection LLT
    20.1 100000004862 10079985 Uncomplicated pyelonephritis LLT
    21.1 100000004862 10081414 Ventilator associated bacterial pneumonia LLT
    20.1 100000004862 10079983 Complicated intra-abdominal infection LLT
    21.1 100000004862 10081416 Hospital acquired bacterial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004261-10 Sponsor Protocol Number: AR-105-002 Start Date*: 2017-10-19
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia
    Medical condition: Pseudomonas aeruginosa pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Completed) HU (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001521-25 Sponsor Protocol Number: NEOMERO-2 Start Date*: 2011-12-15
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial
    Medical condition: Bacterial meningitis in children up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002110-32 Sponsor Protocol Number: 10-0065 Start Date*: 2018-06-13
    Sponsor Name:Regents of the University of Michigan
    Full Title: DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli
    Medical condition: Blood stream Infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB) including XDR-AB, CRE and XDR-PA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004031 Bacterial infection due to other gram-negative organisms LLT
    20.1 10021881 - Infections and infestations 10035701 Pneumonia gram-negative bacterial NOS LLT
    20.1 10021881 - Infections and infestations 10064977 Acinetobacter bacteremia LLT
    20.0 10021881 - Infections and infestations 10051190 Pneumonia Pseudomonas aeruginosa LLT
    20.0 10021881 - Infections and infestations 10035679 Pneumonia due to Escherichia coli (E. Coli) LLT
    20.0 10021881 - Infections and infestations 10054280 Escherichia coli bacteraemia LLT
    20.0 10021881 - Infections and infestations 10021860 Infection Pseudomonas aeruginosa LLT
    20.1 10021881 - Infections and infestations 10023456 Klebsiella pneumonia LLT
    20.0 10021881 - Infections and infestations 10058883 Klebsiella bacteremia LLT
    20.0 10021881 - Infections and infestations 10054218 Enterobacter pneumonia PT
    20.1 10021881 - Infections and infestations 10058884 Enterobacter bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000463-13 Sponsor Protocol Number: MGR001-1010 Start Date*: 2015-05-05
    Sponsor Name:Mylan Pharma UK Ltd
    Full Title: AN OPEN STUDY TO ASSESS THE ROBUSTNESS OF THE CRC749 DEVICE BY PHARMACEUTICAL PERFORMANCE FOLLOWING TWICE DAILY DOSING OF MGR001 ADMINISTERED VIA ORAL INHALATION IN SUBJECTS WITH ASTHMA OR CHRONIC ...
    Medical condition: Asthma or chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003653-26 Sponsor Protocol Number: OVG2011/07 Start Date*: 2011-12-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm.
    Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10039446 Salmonella typhi infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000344-10 Sponsor Protocol Number: Start Date*: 2012-05-24
    Sponsor Name:Medical Research Council [...]
    1. Medical Research Council
    2. Kings College London
    Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial
    Medical condition: S. aureus bacteraemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.1 10021881 - Infections and infestations 10054638 Staphylococcus aureus septicemia LLT
    14.1 10021881 - Infections and infestations 10058863 Staphylococcus aureus bacteraemia LLT
    14.1 10021881 - Infections and infestations 10041943 Staphylococcus aureus septicaemia LLT
    14.1 10021881 - Infections and infestations 10058867 Methicillin-resistant staphylococcal aureus sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 19:25:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA